journal article·2025-03Open access

Recent advances in metallodrug: Coordination-induced synergy between clinically approved drugs and metal ions

Won Kyu Kim, Jong Min An, Yeon Jin Lim, Kihun Kim, Yun Hak Kim, Dokyoung Kim

Abstract

Metallodrugs utilize metal ions as central elements in their structures to exploit unique properties such as coordination actions and redox activity for targeted biological interactions. They offer the advantage of high specificity in attacking diseased cells while minimizing damage to healthy tissues, which is vital in treatments such as chemotherapy. Recently, a new chemical approach in metallodrug has emerged, which is a coordination-induced synergy between clinically approved drugs and metal ions. The coordination of FDA-approved and clinically tested drugs with metal ions can form a drug-metal complex, which can further grow into drug-metal multiple-complexes and drug-metal nano-aggregates. As a next-generation drug repositioning, these complexes can provide unique and enhanced biological activities, with a high possibility for lab-to-market application. Drug-metal complexes are categorized into three main groups based on disease type and biological functions: (1) complexes for antimicrobial therapies, (2) complexes for anticancer therapies, and (3) complexes for new biological functions. This review aims to present an overview of recent advances in the therapeutic metallodrugs designed to understand the new biological functions. We hope that our summary, insights, and perspectives could contribute to future research and development in basic research and translational medicine. • Recent advances in metallodrugs from clinically approved drugs and metal ions are summarized. • A general overview of the design and synergetic bioactivity of metallodrugs is briefed. • Promising strategies and prospects for next-generation drug-metal complex materials are presented.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Metal complexes synthesis and properties · Pharmacological Effects and Toxicity Studies · Lanthanide and Transition Metal Complexes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (84)

Show source-provided references
1. Metallodrugs in medicinal inorganic chemistry10.1021/cr400460s ↗
2. Metallodrugs: an approach against invasion and metastasis in cancer treatment10.1002/2211-5463.13381 ↗
3. Metallodrugs are unique: opportunities and challenges of discovery and development10.1039/D0SC04082G ↗
4. Antibacterial activities of the extracts, fractions and isolated compounds from Canarium patentinervium Miq. against bacterial clinical isolates, BMC Complement Med
5. Contemporary methods for the extraction and isolation of natural products10.1186/s13065-023-00960-z ↗
6. Plants as a source of anti-cancer agents10.1016/j.jep.2005.05.011 ↗
7. The role of chelation in the treatment of arsenic and mercury poisoning10.1007/s13181-013-0344-5 ↗
8. Hyperfine interactions and metal atom dynamics in a number of t-butyl ferrocene derivatives: the counter intuitive effects of ring substitution10.1016/j.ica.2019.118972 ↗
9. Paul Ehrlich (1854-1915) and his contributions to the foundation and birth of translational medicine10.1159/000443526 ↗
10. Introduction
11. The prehistoric period
12. Drug Discovery · 2005 · 12
13. Greece and rome
14. Plant product analogues and compounds derived from them
15. Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention10.1002/ar.22578 ↗
16. Cisplatin in cancer therapy: molecular mechanisms of action10.1016/j.ejphar.2014.07.025 ↗
17. Nedaplatin: a cisplatin derivative in cancer chemotherapy10.2147/CMAR.S35785 ↗
18. Ligand design strategies to increase stability of gadolinium-based magnetic resonance imaging contrast agents10.1038/s41467-019-09342-3 ↗
19. Review of radium-223 and metastatic castration-sensitive prostate cancer
20. Ruthenium complexes as anticancer agents: a brief history and perspectives10.2147/DDDT.S275007 ↗
21. (8-Hydroxyquinoline) gallium(III) complex with high antineoplastic efficacy for treating colon cancer via multiple mechanisms10.1021/acsomega.2c07742 ↗
22. Chemical biology of anticancer gold(III) and gold(I) complexes10.1039/C5CS00132C ↗
23. A concise review on cobalt Schiff base complexes as anticancer agents10.1016/j.poly.2022.115890 ↗
24. Medicinal chemistry of gold anticancer metallodrugs
25. Silver(I) metallodrugs of thiosemicarbazones and naproxen: biocompatibility, in vitro anti-proliferative activity and in silico interaction studies with EGFR, VEGFR2 and LOX receptors10.1093/toxres/tfaa001 ↗
26. Iron metallodrugs: stability, redox activity and toxicity against Artemia salina10.1371/journal.pone.0121997 ↗
27. Interaction of drug based binuclear mixed-ligand complexes with DNA10.1016/j.bmc.2009.06.023 ↗
28. Characterization and biological activity of Pefloxacin–imidazole mixed ligands complexes10.1016/j.ica.2014.05.020 ↗
29. Metal-based biologically active azoles and beta-lactams derived from sulfa drugs10.1016/j.bmc.2016.01.041 ↗
30. Antimicrobial activity of new transition metal complexes of sulfamethoxazole on nhibiter by Staphylococcus aureus, Pseudomonas aeruginosa, Salmonella typhi and Escherichia coli10.1063/5.0027486 ↗
31. Novel β-lactam antibiotic derivative and its complexes: DFT, frontier energy levels, DNA interaction, docking, physicochemical and antimicrobial properties10.1016/j.molstruc.2020.128487 ↗
32. Sceptrin-Au nano-aggregates (SANA) for overcoming drug-resistant Gram-negative bacteria10.1039/D2NH00279E ↗
33. Red-blood-cell-membrane-coated metal-drug nanoparticles for enhanced chemotherapy10.1002/cbic.202100313 ↗
34. Diruthenium(ii,iii) metallodrugs of ibuprofen and naproxen encapsulated in intravenously injectable polymer-lipid nanoparticles exhibit enhanced activity against breast and prostate cancer cells10.1039/C7NR01582H ↗
35. Synthesis of terpolymer-lipid encapsulated diruthenium(II,III)-anti-inflammatory metallodrug nanoparticles to enhance activity against glioblastoma cancer cells10.1016/j.jinorgbio.2019.110984 ↗
36. Self-assembled nanoparticles of diruthenium(II,III)-Ibuprofen anticancer metallodrug
37. Designing metallogelators derived from NSAID-based Zn(II) coordination complexes for drug-delivery applications10.1002/asia.202000815 ↗
38. Hand-ground nanoscale ZnII-based coordination polymers derived from NSAIDs: cell migration inhibition of human breast cancer cells10.1002/chem.201605674 ↗
39. Manganese-fluorouracil metallodrug nanotheranostic for MRI-correlated drug release and enhanced chemoradiotherapy10.31635/ccschem.020.202000188 ↗
40. High-load gemcitabine inorganic-organic hybrid nanoparticles as an image-guided tumor-selective drug-delivery system to treat pancreatic cancer
41. Core-shell functionalized zirconium-pemetrexed coordination nanoparticles as carriers with a high drug content
42. Delivery and release of curcumin by a hypoxia-activated cobalt chaperone: a XANES and FLIM study10.1039/c3sc51530c ↗
43. Circumventing physicochemical barriers of cyclometalated gold(III) dithiocarbamate complexes with protein-based nanoparticle delivery to enhance anticancer activity10.1021/acsami.3c10025 ↗
44. The effect of metal ions (Fe, Co, Ni, and Cu) on the molecular-structural, protein binding, and cytotoxic properties of metal pyridoxal-thiosemicarbazone complexes
45. NSAIDs use and reduced metastasis in cancer patients: results from a meta-analysis10.1038/s41598-017-01644-0 ↗
46. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis10.1053/gast.2003.50008 ↗
47. Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis10.1007/s10549-008-0228-6 ↗
48. Dendrimers for drug delivery10.1039/C4TB00171K ↗
49. ATP-responsive aptamer-based metal–organic framework nanoparticles (NMOFs) for the controlled release of loads and drugs10.1002/adfm.201702102 ↗
50. Enhanced tumor-specific disulfiram chemotherapy by in situ Cu(2+) chelation-initiated nontoxicity-to-toxicity transition10.1021/jacs.9b03503 ↗
51. 5-Fluorouracil: a narrative review on the role of regulatory mechanisms in driving resistance to this chemotherapeutic agent10.3389/fonc.2021.658636 ↗
52. Multiple layer-by-layer lipid-polymer hybrid nanoparticles for improved FOLFIRINOX chemotherapy in pancreatic tumor models10.1002/adfm.201401583 ↗
53. Single-step assembly of DOX/ICG loaded lipid--polymer nanoparticles for highly effective chemo-photothermal combination therapy10.1021/nn400334y ↗
54. Engineering multifunctional DNA hybrid nanospheres through coordination-driven self-assembly10.1002/anie.201810735 ↗
55. A biomimetic coordination nanoplatform for controlled encapsulation and delivery of drug–gene combinations10.1002/anie.201903417 ↗
56. Doxorubicin pathways: pharmacodynamics and adverse effects10.1097/FPC.0b013e32833ffb56 ↗
57. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective10.1007/s00280-016-3003-0 ↗
58. Metal–organic framework nanoparticles
59. Metal–organic framework (MOF)-Based drug/cargo delivery and cancer therapy10.1002/adma.201606134 ↗
60. Metal–curcumin complexes in therapeutics: an approach to enhance pharmacological effects of curcumin10.3390/ijms22137094 ↗
61. Metal complexes of curcumin – synthetic strategies, structures and medicinal applications10.1039/C5CS00088B ↗
62. Metal-curcumin complexes in therapeutics: an approach to enhance pharmacological effects of curcumin10.3390/ijms22137094 ↗
63. The effects of curcumin on diabetes mellitus: a systematic review10.3389/fendo.2021.669448 ↗
64. The effect of curcumin (turmeric) on Alzheimer's disease: an overview10.4103/0972-2327.40220 ↗
65. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice10.4143/crt.2014.46.1.2 ↗
66. Liposomal nanoformulation as a carrier for curcumin and pEGCG-study on stability and anticancer potential10.3390/nano12081274 ↗
67. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications10.2174/092986710790149738 ↗
68. Bioreductive activation and drug chaperoning in cobalt pharmaceuticals10.1039/b707121c ↗
69. Classical and non-classical ruthenium-based anticancer drugs: towards targeted chemotherapy10.1002/ejic.200600723 ↗
70. Impact of albumin on drug delivery--new applications on the horizon10.1016/j.jconrel.2011.09.069 ↗
71. Anticancer nano-delivery systems based on bovine serum albumin nanoparticles: a critical review10.1016/j.ijbiomac.2021.10.040 ↗
72. Anticancer activity of the thiosemicarbazones that are based on di-2-pyridine ketone and quinoline moiety10.1016/j.ejmech.2019.03.027 ↗
73. Para-substituted thiosemicarbazones as cholinesterase inhibitors: synthesis, in vitro biological evaluation, and in silico study10.1021/acsomega.2c08108 ↗
74. A review on metal complexes and its anti-cancer activities: recent updates from in vivo studies10.1016/j.biopha.2024.116211 ↗
75. Strong in vitro and vivo cytotoxicity of novel organoplatinum(II) complexes with quinoline-coumarin derivatives10.1016/j.ejmech.2019.111751 ↗
76. Synthesis, cytotoxic activity and DNA interaction studies of new dinuclear platinum(ii) complexes with an aromatic 1,5-naphthyridine bridging ligand: DNA binding mode of polynuclear platinum(ii) complexes in relation to the complex structure10.1039/C8DT01946K ↗
77. Naproxen platinum(iv) hybrids inhibiting cycloxygenases and matrix metalloproteinases and causing DNA damage: synthesis and biological evaluation as antitumor agents in vitro and in vivo10.1039/D0DT00424C ↗
78. Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action10.1039/C5SC04205D ↗
79. A rationally designed bimetallic platinum (II)-Ferrocene antitumor agent induces non-apoptotic cell death and exerts in vivo efficacy10.1002/chem.202201259 ↗
80. Antitumor activities for two Pt(II) complexes of tropolone and 8-hydroxyquinoline derivative10.1021/acs.inorgchem.1c01763 ↗
81. Dual drug backboned shattering polymeric theranostic nanomedicine for synergistic eradication of patient-derived lung cancer10.1002/adma.201706220 ↗
82. Charge-conversional click polyprodrug nanomedicine for targeted and synergistic cancer therapy10.1016/j.jconrel.2023.03.019 ↗
83. Anti-inflammatory compounds as ligands in metal complexes as revealed in X-ray structural studies10.1080/02603590008050867 ↗
84. Anti-oxidant, in vitro, in vivo anti-inflammatory activity and antiproliferative activity of mefenamic acid and its metal complexes with manganese(II), cobalt(II), nickel(II), copper(II) and zinc(II)10.1080/14756360802361589 ↗